290 related articles for article (PubMed ID: 32993133)
1. RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer.
Mahato AK; Sidorova YA
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32993133
[TBL] [Abstract][Full Text] [Related]
2. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases.
Runeberg-Roos P; Saarma M
Ann Med; 2007; 39(8):572-80. PubMed ID: 17934909
[TBL] [Abstract][Full Text] [Related]
3. Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson's disease.
Mahato AK; Sidorova YA
Cell Tissue Res; 2020 Oct; 382(1):147-160. PubMed ID: 32556722
[TBL] [Abstract][Full Text] [Related]
4. Small-Molecule Ligands that Bind the RET Receptor Activate Neuroprotective Signals Independent of but Modulated by Coreceptor GFR
Jmaeff S; Sidorova Y; Lippiatt H; Barcelona PF; Nedev H; Saragovi LM; Hancock MA; Saarma M; Saragovi HU
Mol Pharmacol; 2020 Jul; 98(1):1-12. PubMed ID: 32362584
[TBL] [Abstract][Full Text] [Related]
5. Structural studies of GDNF family ligands with their receptors-Insights into ligand recognition and activation of receptor tyrosine kinase RET.
Wang X
Biochim Biophys Acta; 2013 Oct; 1834(10):2205-12. PubMed ID: 23085183
[TBL] [Abstract][Full Text] [Related]
6. RET overactivation leads to concurrent Hirschsprung disease and intestinal ganglioneuromas.
Nagy N; Guyer RA; Hotta R; Zhang D; Newgreen DF; Halasy V; Kovacs T; Goldstein AM
Development; 2020 Nov; 147(21):. PubMed ID: 32994173
[TBL] [Abstract][Full Text] [Related]
7. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
8. De novo mutation of GDNF, ligand for the RET/GDNFR-alpha receptor complex, in Hirschsprung disease.
Ivanchuk SM; Myers SM; Eng C; Mulligan LM
Hum Mol Genet; 1996 Dec; 5(12):2023-6. PubMed ID: 8968758
[TBL] [Abstract][Full Text] [Related]
9. RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.
Asai N; Jijiwa M; Enomoto A; Kawai K; Maeda K; Ichiahara M; Murakumo Y; Takahashi M
Pathol Int; 2006 Apr; 56(4):164-72. PubMed ID: 16634961
[TBL] [Abstract][Full Text] [Related]
10. The GDNF/RET signaling pathway and human diseases.
Takahashi M
Cytokine Growth Factor Rev; 2001 Dec; 12(4):361-73. PubMed ID: 11544105
[TBL] [Abstract][Full Text] [Related]
11. Current concepts in RET-related genetics, signaling and therapeutics.
Plaza-Menacho I; Burzynski GM; de Groot JW; Eggen BJ; Hofstra RM
Trends Genet; 2006 Nov; 22(11):627-36. PubMed ID: 16979782
[TBL] [Abstract][Full Text] [Related]
12. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease.
Bordeaux MC; Forcet C; Granger L; Corset V; Bidaud C; Billaud M; Bredesen DE; Edery P; Mehlen P
EMBO J; 2000 Aug; 19(15):4056-63. PubMed ID: 10921886
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient.
Angrist M; Bolk S; Halushka M; Lapchak PA; Chakravarti A
Nat Genet; 1996 Nov; 14(3):341-4. PubMed ID: 8896568
[TBL] [Abstract][Full Text] [Related]
14. The mouse soluble GFRalpha4 receptor activates RET independently of its ligand persephin.
Yang J; Runeberg-Roos P; Leppänen VM; Saarma M
Oncogene; 2007 May; 26(26):3892-8. PubMed ID: 17213820
[TBL] [Abstract][Full Text] [Related]
15. Small Molecules and Peptides Targeting Glial Cell Line-Derived Neurotrophic Factor Receptors for the Treatment of Neurodegeneration.
Sidorova YA; Saarma M
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911810
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic susceptibility to misfolding of a hot-spot for Hirschsprung disease mutations in the ectodomain of RET.
Kjaer S; Ibáñez CF
Hum Mol Genet; 2003 Sep; 12(17):2133-44. PubMed ID: 12915470
[TBL] [Abstract][Full Text] [Related]
17. Recent inventions on receptor tyrosine kinase RET modulation.
Jurvansuu JM; Goldman A
Recent Pat Biotechnol; 2008; 2(1):47-54. PubMed ID: 19075852
[TBL] [Abstract][Full Text] [Related]
18. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.
Sawai H; Okada Y; Kazanjian K; Kim J; Hasan S; Hines OJ; Reber HA; Hoon DS; Eibl G
Cancer Res; 2005 Dec; 65(24):11536-44. PubMed ID: 16357163
[TBL] [Abstract][Full Text] [Related]
19. Loss-of-function mutation of c-Ret causes cerebellar hypoplasia in mice with Hirschsprung disease and Down's syndrome.
Ohgami N; Iizuka A; Hirai H; Yajima I; Iida M; Shimada A; Tsuzuki T; Jijiwa M; Asai N; Takahashi M; Kato M
J Biol Chem; 2021; 296():100389. PubMed ID: 33561442
[TBL] [Abstract][Full Text] [Related]
20. Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-Ret receptor tyrosine kinase.
Trupp M; Raynoschek C; Belluardo N; Ibáñez CF
Mol Cell Neurosci; 1998 May; 11(1-2):47-63. PubMed ID: 9608533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
